礼来CEO亲自表示：服用替尔泊肽，每天减少摄入800大卡！

Core Viewpoint - The article discusses the significant impact of the drug Tirzepatide (Zepbound) on weight loss and its implications for the food industry, highlighting its effectiveness and the growing demand since its approval by the FDA in late 2023 [4][6][12]. Group 1: Drug Efficacy and Impact - After using Tirzepatide, patients reportedly reduce their daily caloric intake by approximately 800 calories, equivalent to one meal [4][5]. - In clinical trials, patients using the highest dosage of Tirzepatide lost an average of 22.5% of their body weight [6]. - A study conducted by Fudan University confirmed that Tirzepatide is safe and effective for weight loss in Chinese adults, with participants losing an average of 16.1 kg over 52 weeks [9][10]. Group 2: Market Dynamics and Competition - Tirzepatide belongs to the rapidly growing GLP-1 drug class, which mimics gut hormones to regulate blood sugar and suppress appetite [8]. - Major competitors in the GLP-1 space include Novo Nordisk, which produces Ozempic and Wegovy, both containing the active ingredient Semaglutide [12]. - The popularity of GLP-1 drugs has led to increased stock prices for companies like Eli Lilly, but concerns remain about potential negative impacts on the food and beverage industry [14].